Welcome to our dedicated page for Theratechnologies news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies stock.
Theratechnologies Inc. was a commercial-stage biopharmaceutical company whose recent news covered product commercialization, financial results, shareholder matters and a completed acquisition. Company updates included the availability of EGRIFTA WR™ (tesamorelin) for injection, an FDA-approved formulation used to reduce excess abdominal fat in adults with HIV and lipodystrophy.
Theratechnologies news also covered quarterly operating results, regulatory and development spending categories, proxy and shareholder voting matters, capital-structure disclosures and governance matters tied to its transition following the completed acquisition by an affiliate of Future Pak.
Theratechnologies (THTX) announced that the USPTO has granted U.S. Patent No. 10,799,562, which protects the use of tesamorelin to treat Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD). This patent, expiring in 2040, is licensed exclusively from Massachusetts General Hospital. The company plans to submit a Phase 3 study protocol to the FDA and European agencies in Q4 2020, aiming to start a trial in Q1 2021 using a new formulation of tesamorelin called “F8.” Intellectual property protections will support commercialization efforts.
Theratechnologies (THTX) will report its Q3 financial results on October 15, 2020. A conference call is scheduled for 8:30 a.m. ET on the same day, hosted by CEO Paul Lévesque. The call invites participation from financial analysts and has a listen-only option for media and the public.
Details for accessing the call include a toll-free number, an international dialing option, and a webcast link. An audio replay will be available later on the same day.
MONTREAL, Sept. 30, 2020 – Theratechnologies (THTX), a biopharmaceutical company, has announced that Dr. Christian Marsolais, the Senior Vice President and Chief Medical Officer, will be presenting at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5, 2020, at 4:30 p.m. ET. Investors and others interested can access a live webcast of the presentation through the provided link, with a replay available one hour post-event.
Theratechnologies specializes in innovative therapies that address unmet medical needs, with further information available on their official website.
Theratechnologies (THTX) announced preliminary results for Q3 2020, expecting consolidated net revenues between $13.8 million and $14.2 million, down from $16.1 million in Q3 2019. The decline is attributed to the COVID-19 pandemic, one-time transitions from EGRIFTA to EGRIFTA SV, and increased rebates. As of August 31, 2020, cash reserves are projected at $27 million. CEO Paul Lévesque highlighted efforts to adapt sales strategies amidst pandemic challenges.
Theratechnologies has announced plans to initiate Phase 3 clinical trials for tesamorelin targeting Non-Alcoholic Steatohepatitis (NASH), anticipated to start in early 2021. The trial will recruit ~650 patients with fibrosis scores of 2 and 3 and a cohort of 50 HIV patients. Early positive data suggest tesamorelin reduces liver fat and fibrosis progression. The investigational formulation, known as F8, is patent-protected in the U.S. until 2033. The company aims for a supplemental Biologics License Application for a multi-dose pen injector in 2022.
Theratechnologies announces the commercial launch of Trogarzo® in Germany as of September 11, 2020, aimed at aiding patients with multidrug-resistant HIV. Trogarzo®, a first-of-its-kind monoclonal antibody, has been filed for health technology assessment with the German health authority and can be marketed during the review process. Experts stress the importance of new HIV treatments, especially during the COVID-19 pandemic. Positive market reception is critical, while the risk of negative reviews and physician adoption remains a concern.